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ABSTRACT
FBXW7 mutations occur in a variety of human cancers including colorectal cancer 
(CRC). Elucidating its mechanism of action has become crucial for cancer therapy; 
however, it is also complicated by the fact that FBXW7 can influence many pathways 
due to its role as an E3-ubiquitin ligase in proteasome degradation. FBXW7 and TP53 
are tumour suppressors intensively implicated in colorectal carcinogenesis. Deletion 
mutations in these two genes in animal models mark the progression from adenoma 
to carcinoma. Although still largely unknown, the last defense mechanism against 
CRC at the molecular level could be through a synergistic effect of the two genes. 
The underlying mechanism requires further investigation. In our laboratory, we have 
used a phospho-kinase profiler array to illustrate a potential molecular link between 
FBXW7 and p53 in CRC cells. In vitro and in vivo assessments demonstrated aberrant 
induction of phosphorylated p53 at Serine 15 [phospho-p53(Ser15)] in human  
FBXW7-deficient CRC cells as compared to their FBXW7-wild-type counterparts. 
FBXW7 loss in HCT116 cells promoted resistance to oxaliplatin. Immunoblotting 
data further confirmed that reduction of phospho-p53(Ser15) may contribute to the 
decreased efficacy of therapy in FBXW7-mutated CRC cells. The findings may suggest 
the applicability of phospho-p53(Ser15) as an indicative marker of FBXW7-mutations. 
Phospho-p53(Ser15) regulation by FBXW7 E3-ligase activity could provide important 
clues for understanding FBXW7 behavior in tumour progression and grounds for its 
clinical applicability thereafter.
INTRODUCTION
FBXW7 (F-box and WD repeat domain-
containing 7, also known as FBW7, AGO, SEL10, CDC4) 
and TP53 are widely-known tumour suppressors and 
their genetic alterations lead to malignant transformation, 
metastatic spread and poor survival of cancer sufferers 
[1–4]. They are among the most commonly mutated genes 
after K-RAS and APC in colorectal cancer (CRC) [5–7]. 
FBXW7 constitutes one of the four subunits of SCF (SKP1-
cullin-F-box)-E3 ubiquitin protein ligase complex, which 
functions in phosphorylation-dependent ubiquitination. To 
date, a wide array of SCFFBXW7 E3-ligase substrates have 
been identified and characterized, including cyclin E [8, 9], 
c-Myc [10, 11], c-Jun [12, 13], Notch [14], Presenilin 
[15], SREBP [16], Aurora-A [17], Krüppel-like factor 
5 (KLF5) [18], DEK proto-oncogene [19], and peroxisome 
proliferator-activated receptor-γ coactivator-1α (PGC-1α) 
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[20]. These and several other SCFFBXW7 E3-ligase substrates 
play central roles in cell division, growth, differentiation, 
cell-fate determination and maintenance of the phenotype 
of a variety of types of stem cells [3, 21–24]. There are 
several comprehensive reviews on FBXW7 functions as 
an E3-ligase in ubiquitin mediated proteasome-degradation 
[1, 3, 8–14].
Recent literature has reported the synergistic 
contribution of FBXW7 and TP53 to the suppression 
of gastrointestinal cancer [15, 16]. FBXW7 has been 
identified as a transcriptional target of TP53 and lower 
expression levels of FBXW7 upon TP53-mutations have 
been reported [15, 17, 18]. Parallel loss of the two tumour-
suppressors was found to cooperate in tumourigenesis [16, 
18, 19]. In line with such data, is the fact that most natural 
FBXW7 mutations in cancers are shown to exhibit a TP53 
mutation [6, 7, 18]. Despite previous reports that FBXW7 
is transcriptionally controlled by p53, little is known about 
their synergistic involvement in the molecular etiology of 
CRC. The p53-dependent relationship, reported in current 
literature, does not fully reveal the interplay between p53 
and FBXW7, and p53 activity modulated by FBXW7-
dependent mechanism(s) is yet unidentified.
Considering the multiple challenges to treatment 
response posed by a mutated tumour suppressor gene, 
elucidating FBXW7’s mechanisms of action could 
be a breakthrough for cancer therapy. More recently, 
a number of groups demonstrated FBXW7-mediated 
drug resistance in human cancer cell lines via FBXW7-
suppression and increased levels of pro-survival factor 
MCL1 and mTOR [20–23]. Wang et al. showed that loss 
of FBXW7 leads to rapamycin drug-resistant by inducing 
Epithelial-Mesenchymal Transition (EMT) in CRC cells 
[21]. However, it is still unclear whether this mechanism 
explains FBXW7 loss-conferred resistance to other 
standard chemotherapeutics such as 5-fluorouracil (5-FU), 
cisplatin and oxaliplatin.
Ultraviolet (UV) and DNA damage agents induced 
protein phosphorylation is one of the earliest events 
in modifying protein stability, and FBXW7 E3-ligase 
mediates the degradation of proteins in a phosphorylation-
dependent manner [1, 3, 8, 24]. FBXW7 influences many 
pathways due to its role as an E3-ligase in proteasome-
degradation. Loss of FBXW7 function is likely to result 
in failed regulation of its downstream targets and cellular 
acquisition of the hallmarks of cancer.
This study investigated the relationship between 
deregulation of FBXW7 E3-ligase activity and p53 
phosphorylation. Our data show aberrant induction of 
phosphorylated-p53 at Serine 15 [phospho-p53(Ser15)] 
in human CRC cells that lacked FBXW7 as compared to 
their FBXW7 wild-type counterparts. TP53 is a key player 
in determining the response of colorectal cancer cells to 
oncogenic stress and chemotherapy by oxaliplatin and 
5-FU [25]. UV-radiation but not oxaliplatin drug induced 
phospho-p53(Ser15) in CRC cells with FBXW7 deletion. 
Despite the accumulation of phospho-p53(Ser15) in 
mutant-FBXW7 CRC-tissues, FBXW7 does not directly 
interact with phospho-p53(Ser15) for degradation. Post-
translational modification of p53 by its phosphorylation 
on Serine 15 has been one of the most extensively studied 
functional switch mechanisms in response to genotoxic 
stress. Serine15 residue of p53 is phosphorylated allowing 
p53 to be released from its normal physiological function 
[26, 27]. Subsequently, p53 stabilizes in the nucleus to 
act as a transcriptional activator for tumour suppression, 
implicating phospho-p53(Ser15) as a marker of FBXW7-
associated carcinogenesis.
RESULTS
FBXW7 loss leads to induction of  
p53-phosphorylation at Serine-15
Ablation of FBXW7 was shown to elevate the level 
of phosphorylated-substrate protein and its downstream 
signaling proteins. Such a phenomenon could inform 
about the disease mechanisms of colorectal carcinogenesis 
and the cellular pathways affected by homeostatic 
deregulation caused by an FBXW7 mutation. Post-
translational modification of p53 by phosphorylation may 
be an important mechanism underlying regulation of p53 
stabilization and function. However, the molecular and 
cellular mechanisms that link FBXW7 and p53 following 
phosphorylation are unclear. An in vitro human phospho-
kinase array (HPKPA) with multiple p53-phosphoacceptor 
sites (Figure 1A), was used to assess changes to the 
protein phosphorylation profile. We and others have 
reported that HCT116 and DLD-1 cell-lines harboring 
wild-type FBXW7; FBXW7(+/+), or inactivated FBXW7; 
FBXW7(−/−), have the characteristics of human CRC 
cells without or with FBXW7-mutation [19, 20, 23, 28]. 
In particular, they provide an excellent in vitro model to 
delineate the molecular mechanisms that contribute to 
neoplasia. Remarkably, in the absence of FBXW7, both 
HCT116 and DLD-1 showed a substantial increase in 
p53 phosphorylation at Serine-15 as compared to control 
cells (Figure 1F), while phosphorylation at Serine-46 and 
Serine-392 remain unchanged (Figure 1, 1B vs. 1D and 1C 
vs. 1E). Western blot analysis showed an increase of p53 
phosphorylated at Ser-15 in FBXW7(−/−) versus wild-type 
FBXW7(+/+) (Figure 1G).
The Ser15 phosphorylation site is evolutionarily 
conserved and corresponds to Ser18 of murine p53, 
which has not been as extensively examined as that of 
human p53. Mice harbouring an fbxw7 allele in which 
exon5 was flanked by two loxP sites were crossed to 
villin-cre transgenic mice as previously described [28, 
29] (Figure 2A). We examined p53 phosphorylation in 
mouse intestinal tissues harboring fbxw7 deletion. We 
detected enhanced phosphorylation of p53 at Serine-18 
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Figure 1: Human phospho-kinase-profiler-array (HPKPA) revealed induction of phospho-p53(Ser15) in FBXW7-null 
human CRC cells [FBXW7(−/−) vs. FBXW7(+/+)]. A. Schematic representation of the coordinates of the pre-coated phospho-
specific antibodies in duplicate in a nitrocellulose-membrane. Dashed red-circle highlights the antibody position for phospho-p53(Ser15). 
B-E. Outcome overview of the HPKPA using human CRC-cells expressing and lacking FBXW7; FBXW7-deficient HCT116 (D) and 
DLD-1 (E) cells [FBXW7(−/−)], compared to parental HCT116 (B) and DLD-1 (C) cells [FBXW7(+/+)]. F. The expression of phospho-
p53(Ser15) protein was significantly increased. Scanned values obtained using transillumination scanner of phospho-p53(Ser15) and 
Positive Controls (PCs) spots as corresponding to HCT116 and DLD-1 cell lines in B-E. The results shown are representative of experiments 
performed at three independent times. G. Phospho-p53(Ser15) expressions was analyzed by Western blotting analysis. Protein extracts 
isolated from HCT116 and DLD-1 cell lines with FBXW7(-/-) and FBXW7(+/+) alleles were Western blotted for phospho-p53(Ser15) 
antibody and Tubulin (loading control).
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with the phospho-specific p53 (Ser15) antibody [30]. 
Phosphorylation of Serine-18 regulates distinct p53 
functions in mice, including p53-dependent transcripton, 
apoptosis, and cell cycle arrest after DNA damage 
[30]. There was accumulation of phosphorylated p53 
at Serine-18 but despite the high levels of phospho-
p53(Ser18), there was only a very small increase in total 
levels of p53 (Figure 2B).
FBXW7-dependent induction of phospho-
p53(Ser15) in CRC cells treated with UV 
radiation
FBXW7 is involved in the control of genetic 
instability [16, 19]. A strong association has been found 
between phosphorylation of p53 on Serine-15 and 
exposure to UV irradiation [31, 32]. In order to evaluate 
Figure 2: Induction in the level of the of murine phospho-p53(Ser18) in the intestine of fbxw7ΔG mice. A. Schematic 
shows the floxed Fbxw7 allele (fbxw7fl/fl) before and after villin-Cre recombination to generate gut-specific conditional Fbxw7 inactivation 
(fbxw7ΔG) mice. B. Western blot analysis of fbxw7fl/fl and fbxw7ΔG intestinal proteins using antibodies against Fbxw7, p53, phospho-
p53(Ser15), and the loading control β-actin. Experiments were performed on at least two independent occasions.
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phospho-p53(Ser15) induction’s dependence on FBXW7 
in UV-treated CRC cells, we used HCT116 cells harboring 
wild-type and inactivated FBXW7. Immunofluorescence 
(IF) staining showed nuclear phospho-p53(Ser15) was 
almost undetectable in control HCT116FBXW7(+/+) cells, but 
was markedly increased in FBXW7-null HCT116FBXW7(−/−) 
cells (Figure 3, 3E vs. 3B; 3F vs. 3C and 3M). This finding 
was supported by Western blot (WB) analysis (Figure 3N). 
In addition, we applied UV-treatment to the HCT116 cells 
to provide clearly distinguishable results. Treatment with 
UV-radiation enhanced phospho-p53(Ser15) induction in 
both the wild-type and FBXW7-mutated cells (Figure 3, 
3H & 3K; 3M, right panel). Nonetheless, phospho-
p53(Ser15) in HCT116FBXW7(−/−) cells was markedly higher 
than that in HCT116FBXW7(+/+) cells, with both cytoplasmic 
and nuclear localization (Figure 3, 3K vs. 3H; 3L vs. 3I). 
The WB data were consistent with the IF results (Figure 3, 
3M and 3N). Our results validated the enrichment of 
phospho-p53(Ser15)-induction in FBXW7-deficient 
CRC cell lines. Subsequently we further investigated 
whether phospho-p53(Ser15) could provide diagnostic 
and/or prognostic value for CRC-biopsies with FBXW7-
mutations.
Phospho-p53(Ser15) protein accumulation in 
human CRC-tissues with FBXW7-mutation
We carried out in vivo investigations to validate 
the phospho-p53(Ser15) induction in CRC tissues 
excised from patients with FBXW7-mutated tumours. 
Immunohistochemical (IHC) comparison of phospho-
p53(Ser15) expression in wild-type and FBXW7-mutated 
human CRC-tissue was carried out. The intensity of the 
IHC staining observed in the two tissue types (wild-
type vs. mutants for FBXW7), was evaluated in a semi-
quantitative manner. In CRC tissues, the architecture 
of the gut wall was chaotic as expected for both cancer 
specimens: FBXW7- wild-type (control) and -mutant 
(Figure 4, 4C-4F). Irregular and distorted crypts were 
evident invading the submucosal area of CRC tissues 
(Figure 4E, 4F). Expression of phospho-p53(Ser15) 
protein was completely lost in FBXW7 wild-type tissue 
(Figure 4C, 4D) [mean staining-score; 0.33 (Figure 5A)], 
irrespective of the tumour-type or the presence of p53-
mutation. On the contrary, FBXW7-mutant CRC showed 
substantial of phospho-p53(Ser15) induction in the 
mucosa and early submucosal invasion (Figure 4E, 4F) 
[mean staining-score; 1.87 (Figure 5A)]. Healthy human 
small bowel tissue, which was available as an additional 
control, exhibited a consistent distribution of phospho-
p53(Ser15) protein in the mucosal lining of the structured 
bowel wall architecture (Figure 4A, 4B) [mean staining-
score; 1.50 (Figure 5A)]. In general, phospho-p53(Ser15) 
was enriched in the intestinal crypts, but was much 
less in the differentiated cell types residing in the villi 
(Figure 4B). This may suggest that phospho-p53(Ser15) 
could be detected in cancer and crypt-based cells which 
exhibit poor differentiation in contrast to the cells of the 
villi. Collectively, compared to the negligible expression 
in control CRC tissues, remarkable accumulation of 
phospho-p53(Ser15) protein was observed in FBXW7-
mutant samples.
Even though TP53 mutations have been reported in 
over 50% of human tumours [33], it was not possible to 
profile the TP53 status by molecular methods in the CRC-
tissues utilized in our previous studies (Ian Tomlinson, 
personal communication) [28, 29]. However, our data 
show heterogeneous pattern of p53-staining. There was 
more p53 staining at the invasion front of CRCs with a 
small increase (not statistically significant) in total levels 
of p53 (p = 0.072) among CRC tissues with FBXW7-
mutation (Figure 6, 6A-6E & data not shown). Of interest 
was the fact that the only controlled variable for the 
wild-type CRC-tissues examined was the presence of 
intact FBXW7. Similarly, the only controlled variable 
for the FBXW7-mutated tissues was the presence of an 
FBXW7 mutation with other cancer mutations remaining 
unidentified. Regardless of the unknown nature of the 
non-FBXW7 mutations, the presence of an FBXW7-
mutation alone was adequate to give a consistent pattern of 
phospho-p53(Ser15) induction (mean-range; 1.67–2.33). 
Statistical analysis confirmed that phopsho-p53(Ser15)-
induction in FBXW7-mutant tissues was highly significant 
(p < 0.0005) (Figure 5B). Although only a limited number 
of samples was available, the results pointed towards 
the suitability of phospho-p53(Ser15) induction as an 
independent indicative marker of CRC with FBXW7-
mutation.
Loss of FBXW7 leads to oxaliplatin drug 
resistance in CRC cells through differential 
expressions of the TP53 family of transcription 
factors
To evaluate the cytotoxicity of oxaliplatin in CRC-
cells harboring FBXW7-deletion, both HCT116FBXW7(+/+) 
and HCT116FBXW7(−/−) cells were treated with increasing 
concentration of oxaliplatin (0.05 to 25.6 μM), separately, 
for 3 days. SRB assays were performed, dose-response 
curves generated and IC50 values calculated. The assay 
was carried out in triplicate and repeated at least three 
times. The Student’s t-test was used to value the statistical-
significance. The results showed that FBXW7-mutated 
HCT116FBXW7(−/−) cells conferred resistance to oxaliplatin 
drug (Figure 7, 7A-7C). IC50 of HCT116FBXW7(−/−) for 
oxaliplatin was almost four times higher than the IC50 
of the corresponding FBXW7-wild-type cell line. Indeed, 
the IC50 of HCT116FBXW7(+/+) cells for oxaliplatin was 
about 0.6567 μM and that of HCT116FBXW7−/− cells was 
about 2.398 μM (Figure 7A). The results show that 
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Figure 3: In vitro validation of phospho-p53(Ser15) accumulation in FBXW7-deficient human CRC cells. A-L. 
Immunofluorescent staining of phospho-p53(Ser15) protein (red) in non-treated (A-F) and 50 kJ/m2 UV-treated (G-L) HCT116 cells. UV 
stimulated induction of phospho-p53(Ser15) protein in general (H & K). In both conditions, FBXW7-deficient cells (E & K) obtain higher 
expression levels of phospho-p53(Ser15) than the corresponding control cells (B & F). Nuclei were visualized with 4′, 6-diamidino-2-
phenylindole (DAPI)-blue fluorescent stain (A, D, G, and J). Overlaid images (C, F, I, and L) showed nuclear localization of phospho-
p53(Ser15). Arrows indicate phospho-p53(Ser15) distribution. Bars, 25 μm. Figures are representative of duplicate experiments performed 
on three separate occasions. M. Quantification analysis of fluorescence intensity of IF images. N. Western blotting analysis of phospho-
p53(Ser15) expression; untreated and exposed to 50 kJ/m2 UV. β-actin served as a loading control. All experiments were repeated at least 
three times.
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FBXW7-deleted cells demonstrated higher tolerance to the 
effects of oxaliplatin drug (Figure 7, 7B, 7C & data not 
shown). IC50 values for control HCT116 cells with wild-
type FBXW7 are consistent with previously reported values 
for the same drugs [34]. The data suggest that FBXW7 loss 
confers HCT116 cells resistance to oxaliplatin.
To address the hypothesis of an existing relationship 
between mutated-FBXW7 and phopsho-p53(Ser15) 
protein in response to drug treatment, the expression level 
of phopsho-p53(Ser15) protein was assessed by Western 
blotting (Figure 7D). In contrast to UV-irradiation, 
Western blotting results showed that expression 
of phospho-p53(Ser15) decreased after oxaliplatin 
treatment (Figure 7D) in HCT116FBXW7−/− cells. Hence, 
the decreased phospho-p53(Ser15) on its own might not 
affect the cell’s ability to induce apoptosis. To assess 
the impact of loss of FBXW7 and TP53-mediated gene 
expression on HCT116FBXW7(−/−) cells behavior, mRNA 
was isolated from equal numbers of HCT116FBXW7(+/+) 
and HCT116FBXW7(−/−) cells (Figure S1). The differential 
expression of members of the TP53/TP63/TP73 family of 
transcription factors and apoptosis-related TP53-mediated 
gene expression (TP53AIP1 and TP53BP2) was analyzed 
by real-time-PCR [35] (Table S1). The analysis highlights 
significant up-regulation of TP63 in HCT116FBXW7(−/−) 
cells while both TP53 and TP73 expression appeared to 
be down-regulated (Figure 7E). Apoptosis-stimulating 
protein of TP53AIP1 and TP53BP2 expression was 
simultaneously down-regulated (Figure 7E). The result 
may suggest that induction of phopsho-p53(Ser15) by 
loss of SCFFBXW7-E3-ligase activity could contribute to 
other pathways function to block the p53 activation [27] 
and consequently decreased efficacy of therapy in chemo-
resistant CRCs.
Figure 4: IHC validation of phospho-p53(Ser15) accumulation in FBXW7-mutant human CRC-tissues. A-F. 
Representative images of chromogenic IHC-staining of paraffin-embedded FBXW7-wild-type (wt) and -mutated (mut) CRC-tissue sections 
for phospho-p53(Ser15) expression. Specimens of healthy small bowel (n = 1) (A and B), FBXW7-wt CRC (C and D), and FBXW7-mut 
CRC (E and F) show enrichment, annihilation, and remarkable increment of phospho-p53(Ser15) expression. Bars, 50 μm (A, C, E); 
100 μm (B, D, F).
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Figure 5: Phospho-p53(Ser15) expression scores in sections from CRC-tissues with and without FBXW7-mutations.  
A. IHC for human CRC-tissues evaluated semi-quantitatively by two independent observers within 3-microscopic views in the individual 
slides. Expression scale of the phospho-p53(Ser15) protein was determined by the intensity of the staining, and thus scored using an ordinal 
scale: 0 = no staining, 1 = lowest staining, 2 = intermediate staining and 3 = extensive staining. B. P value (***p < 0.0005; mean ± S.D.; 
mean for FBXW7WT group = 0.31 with S.D = 0.1945; and mean for FBXW7Mut group = 1.87 with S.D. = 0.3600) was gained from Student’s 
t-test comparing phospho-p53(Ser15) expression in CRC-tissues with and without FBXW7-mutations.
Oncotarget9248www.impactjournals.com/oncotarget
Phospho-p53(Ser15) may not be a direct target 
of SCFFBXW7-E3 ubiquitin ligase
In the present studies, we demonstrated through 
several lines of evidence that FBXW7 ablation in CRC 
cells results in the accumulation of phospho-p53(Ser15). 
The mechanism of this is still uncertain. We therefore 
studied the FBXW7/p53-correlation further to validate 
the phospho-p53(Ser15) phenomenon. Consistent with 
the HPKPA results, mutations at either Ser46 (S46A) or 
Ser392 (S392A) did not stabilize phospho-p53(Ser15) in 
the presence of FBXW7 (Figure 8A). Western blotting 
data with cells that overexpress the p53(S15A) mutant 
protein also determined the anti-phospho-p53(Ser15) 
antibody specificity (Figure 8A). Furthermore, co-
expression of FBXW7 decreased the steady-state levels 
of p53(wt) (Figure 8B). We next examined whether the 
FBXW7 protein would bind to p53 protein and vice versa. 
Immunoprecipitation (PI) of either FLAG epitope-tagged 
p53 or GFP fused-FBXW7α showed no interaction 
between these proteins (Figure 8C). These data suggest 
that FBXW7 does not act directly, but indirectly regulates 
the abundance of phospho-p53(Ser15).
Furthermore, high levels of phosphorylation of 
p53 at Serine-15(Ser15), modulate cell cycle checkpoint 
kinase Ataxia-Telangiectasia Mutated (ATM) and 
Ataxia-Telangiectasia and Rad3-related (ATR) that 
impede MDM2 binding to p53 and subsequently 
promote p53 accumulation and activation in response 
to DNA damage [32, 36]. Phosphorylation of Serine 15 
is considered to be an initiating and nucleating event in 
p53 activation, especially in combination with Ser20 
and Thr18 phosphorylation. ATM and ATR kinase 
however, in turn, activates the effector kinase such Chk2 
and ERK to phosphorylate Ser15, along with several 
other residues in p53 [37–39]. Following p53 Ser15 
Figure 6: p53 levels remained unchanged in FBXW7-mutant human CRC-tissues. A-D. IHC for p53 in human CRC with 
(C, D) and without (A, B) FBXW7 mutations. Boxed line indicates magnified tissue area. Scale bars; 50 μm. E. Western blotting analysis 
of p53 expression in HCT116 and DLD-1 cell lines expressing or lacking FBXW7. β-actin was blotted for loading control. All experiments 
were repeated for two times.
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phosphorylation, protein kinase CK1 can also sequentially 
phosphorylate Thr18 using the phosphorylated Ser15 as 
a recognition determinant [40, 41]. Given these findings, 
we examined the level of these kinases in both HCT116 
and DLD-1 cells lacking and expressing FBXW7. Both 
Chk2 phosphorylation at Ser516, and Thr68 protein 
levels were slightly increased in HCT116(−/−) and 
DLD-1(−/−) cells compared with control (+/+) cells, 
whereas CK1α level remarkably increased, especially its 
long isoform (Figure 8D). Total (phosphorylated and non-
phosphorylated) levels of ERK 1/2 remained unchanged 
(Figure 8D). CK1α has two alternatively spliced isoforms, 
one short (known as CK1αS) and one long (known as 
CK1αL). Both human CK1α isoforms contain a common 
12-amino-acid short insert located at the carboxyl terminus, 
whilst CK1αL itself includes a 28-amino-acid long insert 
(i.e. encoded from exon 5 of CK1αL gene) located in the 
central kinase catalytic domain [42, 43]. Therefore, human 
CK1α isoforms are composed of 365 or 337 amino acids 
due to presence or absence of the exon 5. Consistent with 
Western blotting data, immunofluorescent staining showed 
remarkably increased expression levels of a nuclear splice 
form of CK1α (Figure 8E). Further analysis, beyond the 
current scope of this paper, would be required to validate 
the possibility that FBXW7 could modulate phospho-p53 
via targeting CK1α for degradation.
DISCUSSION
Our experiments do not point to phospho-
p53(Ser15) as a direct binding substrate for FBXW7 E3-
ubiquitin ligase degradation. Cellular stress generated by 
accumulation of FBXW7-substrates (for example, Cyclin 
E and c-Myc) may induce the TP53 pathway via phospho-
p53(Ser15) induction [44, 45]. However, in the colon/
intestine, we and others have shown that expression of 
c-Myc and Cyclin E were unaffected by loss of intestinal/
colonic-fbxw7 [18, 28, 29, 46]. This could suggest a 
potential route for FBXW7 regulating phosphorylated 
p53 protein expression through controlling upstream 
kinases. Considering the fact that CK1α is an essential 
Figure 7: FBXW7 deficiency induces oxaliplatin drug resistance property of HCT116 CRC cells. After starvation 
overnight, synchronised HCT116FBXW7(+/+) and HCT116FBXW7(−/−) cells were treated with increasing concentrations of the oxaliplatin; for 
72 h, IC50 A. and cell viability B. determined using SRB at 540 nm in a microplate reader. C. An increased colony forming efficiency of 
FBXW7–/– HCT116 cells compared with parental FBXW7+/+ HCT116 cells and graphs show mean ± SEM of assay data, representative 
of six replicates in three independent experiments (*P < 0.05, **P < 0.01, ***P < 0.001). D. phospho-p53(Ser15) protein expression 
measured at low (0.35) and IC50 dose (0.7 μM) oxaliplatin concentration in HCT116FBXW7(+/+) and HCT116FBXW7(−/−) cells by Western blotting. 
E. p53-mediated genes expression was determined by qRT-PCR in HCT116FBXW7(−/−) cells (red), first normalized to GAPDH followed by 
normalization to HCT116FBXW7(+/+) cells (blue). Data are mean ± SEM (*P ≤ 0.05; **P < 0.01; ***P < 0.001). Experiments were performed 
in triplicate for each genotype and repeated at least on three independent occasions.
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Figure 8: phospho-p53(Ser15) is regulated by FBXW7 but not through direct interaction. A. FLAG-tagged versions of 
the indicated p53 mutant and GFP-FBXW7 proteins were expressed in HEK293T cells, and lysates were subjected to immunoblotting with 
anti-FLAG, anti-p-p53(Ser15) and anti-GFP. β-actin was used as a loading control. B. HEK293T cells were treated with cycloheximide 
(CHX) for the indicated time points. Lysates were examined by Western blotting anti-p-p53(Ser15) and anti-GFP. β-actin was used as a 
loading control. C. Western blot analysis of whole-cell lysates (input) (left-panel) and immunoprecipitates (IP) with GFP (middle-panel) 
and FLAG-p53 (right-panel) derived from 293T cells transfected with GFP-FBXW7 together with the FLAG-p53 constructs. Thirty hours 
after transfection, cells were pretreated with 10 μM MG132 for 4 h to block the proteasome pathway before cell collection. Both IPs was 
probed by anti-GFP and anti-FLAG antibodies simultaneously. D. HCT116 and DLD-1 cells lacking or expressing FBXW7 were subjected 
to immunoblotting with anti-CK1α, pChk2 (S516), pChk2 (T66), phospho-p44/42 MAPK (pERK1/2) and p44/42 MAPK (ERK1/2). 
β-actin was loaded as a loading control. All experiments were repeated at least three times. E. Immunofluorescent staining of anti-CK1α 
of HCT116FBXW7(+/+) versus HCT116FBXW7(−/−) cells. F. Schematic of molecular changes may occur in the HCT116FBXW7(−/−) compared with 
parental HCT116FBXW7(+/+) cells treated with the oxaliplatin.
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regulator of p53 phosphorylation [40, 41, 47], this study 
provides the possibility that FBXW7 could modulate 
phospho-p53 via targeting CK1α for degradation. 
Therefore, it could be postulated that loss of FBXW7 
could result in CK1α accrual in vivo, which subsequently 
leads to increased p53 stabilization and activation. 
Indeed, we and other recently demonstrated that neither 
FBXW7 abolishment nor CK1α deletion in vivo caused 
immediate intestinal tumour formation [28, 29, 48], 
possibly due to compensation from the p53 pathway 
[16, 48]. Furthermore, we have previously shown an 
up-regulation of β-catenin in HCT116(FBXW7−/−) 
cells [28]. β-catenin is phosphorylated by CK1 (EMBO 
J. 2002 Apr 2;21(7):1733–42). Moreover, CK1α role 
in malignancy is still ambiguous as it was previously 
reported as an oncogene [49] and it may also function 
as a tumour suppressor gene [50]. There are, as yet, no 
in vivo or in vitro data showing a direct link between 
CK1α. and p53 Ser15. On the other hand, our data 
suggest that FBXW7 could be an upstream regulator of 
p53 and CK1α. Considering the possibility that CK1α 
might act as an important co-effector protein linking 
FBXW7 and other cellular pathways, such as Wnt and 
p53, in this respect, we may hypothesis a synergistic 
role for FBXW7 and p53 in suppression of intestinal 
tumourigenicity and metastasis. Moreover, of interest, 
are the observations that suggest that wild-type TP53 in 
tumours may not have the same transcriptional activity 
often found in their non-transformed counterpart 
tissues [51]. Hence, further studies are required to prove 
a possible association between CK1α and p53(Ser15), 
and provide significant evidence for CK1α-mediated up-
regulation phospho-p53(Ser15) in tumours with FBXW7 
mutations. Furthermore, these data may also prompt 
us to reconsider the status of p53 phosphorylation in 
relation to expression of different isoforms of CK1α 
kinase. This may be explained by its diverse roles in 
different cellular processes [52, 53] and by the distinct 
functions and subcellular locations of its two splicing 
variants.
Taken together, the results from cytotoxicity and 
viability assays suggest that loss of FBXW7 function can 
confer resistance to DNA-damage agent oxaliplatin in 
CRC cells. FBXW7 might act as a core factor in different 
mechanisms used by cancer cells to become resistant to 
chemotherapeutic drugs. Determining these mechanisms 
of eluding DNA damaging agents, probably through the 
modulation of SCFFBXW7 protein substrate(s), may be 
crucial for understanding tumour development and its 
response to current chemotherapy. It has been shown that 
p53(Ser15) phosphorylation can stimulate p53 activity. 
In contrast, it was also found that phosphorylation of 
Serine-15 can block binding of p53 to transcription 
Factor II D, and inhibit the formation of a DNA promoter 
complex for transcription [27].
Widely-accepted evidence reveals that tumours 
exhibit a different type and substantially a greater degree 
of p53-phosphorylation than normal cells rendering 
in this way the tumour suppressor nonfunctional [51]. 
Recently, reports showed that p53 up-regulates FBXW7 
[15, 17] whereas it represses ZEB family transcriptional 
regulator (ZEB1 and ZEB2), implicated in epithelial-
mesenchymal transition (EMT) [54]. Western blotting and 
immunohistochemistry data did not exhibit statistically 
significant differences in total p53 protein levels in 
HCT116FBXW7−/− cells and FBXW7-mutated CRC tissues, 
compared with parental HCT116 cells which have 
functional wild-type TP53, and FBXW7-wild-type CRC 
tissues (Figure 5). There is a lot of research activity as 
to whether, and how, TP53 family members interact 
or conflict with each other in apoptosis and tumour 
suppression [55]. Induction of death of neurons and 
mouse embryo fibroblasts by p53 requires coalescence 
of p63 and p73 [56], while not required for the induction 
of apoptosis in T cells [57]. DeltaNp63 isoform of p63 
have been associated with transcriptional activation of 
ATM and p53 Serine-15 phosphorylation in immortalized 
human keratinocytes [58]. However, consistent with 
the recent published data [59], we did not observe any 
significant changes in levels of ATM kinase from protein 
extracts isolated from HCT116 and DLD-1 cell lines with 
FBXW7(−/−) and FBXW7(+/+) alleles in a WB analysis 
(data not shown). Whether FBXW7-mutation induces EMT 
via p53/p63/p73 regulation or vice versa, and provides a 
possible explanation for the prominent chemoresistance 
observed in CRC, remains to be elucidated.
Based on our results, further work to investigate the 
cellular mechanisms implicated in the phospho-p53(Ser15)/
FBXW7 phenomenon are necessary to provide more insight 
into the underlying mechanisms. Following validation 
of the phospho-p53(Ser15) protein induction, an enquiry 
was raised whether such stimulation serves any function 
within the tumour other than its use as an indicative marker 
of FBXW7-mutations. Does the phospho-p53(Ser15) 
induction serve any role in the FBXW7-associated 
carcinogenesis due to a likely gain/loss/change of P53/
P63/P73 function? Our current data as presented are limited 
to few tumour specimens. To assess if FBXW7 mutation 
confers resistance to oxaliplatin relevant to prognosis or 
treatment response, further studies should be carried out 
using a large number of patients treated with oxaliplatin.
MATERIALS AND METHODS
Human colorectal cancer (CRC) tissues
Paraffin-embedded human colorectal tumour 
tissue sections, wild-type (FBXW7WT CRC) and positive 
for FBXW7-mutation (FBXW7Mut CRC) were kindly 
provided by the molecular and population genetics 
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laboratory, Wellcome Trust Centre, University of Oxford. 
The ethical and R&D approval for use of human tissue 
was obtained from the local research-ethics committee and 
Trust R&D office, in Oxford and Nottingham, as described 
previously [28].
Human phospho-kinase profiler array (HPKPA)
In order to identify signaling pathways altered 
by FBXW7, a human phospho-kinase array kit (R&D 
Systems, UK) was used. This consists of a nitrocellulose 
membrane (Figure 1A) having control antibodies 
against phosphorylated proteins which are spotted in 
duplicate. It allows the detection of the relative levels of 
phosphorylation of protein/kinase phosphorylation sites 
(antibodies for those sites were selected and spotted in 
duplicate on nitrocellulose membrane).
Two CRC cell lines (HCT116 and DLD-1 
cells) harboring wild-type-FBXW7; FBXW7(+/+), 
or inactivated FBXW7(−/−), were rinsed with PBS, 
solubilized in the Lysis Buffer supplied with kit and 
with Halt Protease and EDTA-free Phosphatase Inhibitor 
Cocktail (100X) was added as 1:100 concentration 
(Pierce, UK). The lysates were gently rocked at 4°C for 
30 min and then centrifuged at 14, 000x g. The protein 
was quantified using the Bradford protein assay (Bio-
Rad) and the four different cell lysates were adjusted 
to 100 μg in 1ml of array buffer supplied with the kit. 
After blocking the nitrocellulose membrane by rocking 
in Buffer 1 for 1 hour at room temperature, diluted lysate 
contain 100 μg protein was added and incubated on a 
rocking platform overnight at 4°C. Washing with wash 
buffer was followed by adding the diluted detection 
antibody cocktail to corresponding part of the membrane 
and incubation for 2 hours at room temperature on a 
rocking platform. Another wash was carried and the 
membranes were incubated with diluted Streptavidin-
HRP for 30 min then followed by another washing. The 
spots were detected using enhanced chemiluminescence 
(ECL) using the FlourChem FC2 imaging system (Alpha 
Innotech).
Immunohistochemistry (IHC) and 
immunofluorescence (IF)
Paraffin-embedded tissue sections were dewaxed, 
rehydrated as described [28, 60]. Peroxidase activity in 
tissue samples quenched with 1.6%H2O2 (5.33 ml of 
30%H2O2 [Fisher] added in 94.67 ml of PBS) for 10 min, 
and sections washed with PBS for 5 min. The specimen 
region on each section slide circled with a wax PAP-pen, 
and incubated for 30 min in 100 μl Serum-blocking buffer/
slide (10%[v/v] normal-serum and 1%[w/v] Bovine-
Serum-Albumin (BSA) in PBS. The sections incubated in 
primary and biotinylated-secondary-antibody for 1 hr at 
RT, respectively, followed by PBS wash for 3 × 3 mins. 
Antibodies freshly prepared by diluting original primary 
or secondary-antibody appropriately in 1% BSA/PBS.
Tissues then incubated with Avidin-Biotin-Complex 
for 30 min as per manufacturer’s instruction, followed by 
PBS wash for 3 × 3 mins. Staining visualized using DAB 
(3, 3′-diaminobenzidine tetrahydrochloride-dehydrate)-Kit 
[BioGenex] by chromogenic-reaction with DAB-solution 
for 2~10 mins according to manufacturer’s instruction. 
Sections monitored microscopically until optimal-
staining was achieved, and the DAB-reaction quenched 
by dH2O-dilution. Slides counterstained with 60%-Light-
Haematoxylin (v/v). Primary-antibody concentrations 
were as follows: anti-p53 (1:50; Dako, DO-7-clone) 
[61] and anti-phospho-p53(Ser15) (1:100; Santa-Cruz; 
sc-101762) or anti-phospho-p53(Ser15) (1:100; Cell 
Signaling; D4S1H) [62, 63]. For IF, samples exposed to 
goat anti-rabbit antibodies conjugated to Alexa-Fluor 594 
(1/500; Invitrogen) and/or rabbit anti-mouse antibodies 
conjugated to Alexa-Fluor 488 (1/500; Invitrogen).
Ultraviolet (UV)-irradiation
Prior to UV-treatment, the cells were starved in 
RPMI-medium containing 0.1%-FBS for 24 hrs. UV-
treatment performed at 50 kJ/m2 using Spectrolinker-
XL-1000 UV Cross-linker device (Spectromics). 
Following UV-irradiation, cells incubated for 60 mins in 
complete-RPMI-medium at 37.5°C, 5%-CO2.
Cell culture, transfection, and Western blot 
(WB) analysis
In vitro analyses were performed by using HCT116 
human colon carcinoma cell line deleted for FBXW7 in 
single (HCT116FBXW7+/−) or both alleles (HCT116FBXW7−/−) 
in parallel to the control HCT116FBXW7+/+ cell line, which 
were extensively characterized in our laboratory and 
others [19, 20, 28]. Transfection of cell lines HEK293 
or HCT116 depending on the experiment with DNA 
plasmids were carried out using Ployethylenimine (PEI) 
transfection reagent according to the manufacturer’s 
instructions. The protein was extracted using RIPA buffer, 
as described previously [28, 60]. Eluted proteins in SDS-
loading buffer (2×), boiled at 95°C for 4 mins, separated 
on 8%-SDS-PAGE and transferred to polyvinylidene-
fluoride-membranes. p53 mutants were generated with 
the QuikChange XL Site-Directed Mutagenesis Kit 
(Stratagene) according to the manufacturer’s instructions. 
Proteins immunoblotted with primary-antibodies; rabbit 
phospho-p53(Ser15) (1:1000; Cell Signaling), anti-p53 
(1:1000; Dako), anti-phospho-p53(Ser15) (1:1000; Santa-
Cruz), mouse phospho-p53(Ser18) antibody (1:500; 
R&D), Fbxw7 (1:500; Bethyl Laboratories), β-Actin 
(1/10, 000; Abcam), and phospho-p44/42 MAPK (Erk1/2), 
p44/42 MAPK (Erk1/2), pChk2 (T68), pChk2 (S516), (all 
1:1000) were purchased from Cell Signaling Technologies 
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and CKIα from Novus. Secondary-antibodies were HRP-
linked goat anti-mouse and goat anti-rabbit antibodies 
(1/10, 000; Santa-Cruz). Blots were developed using ECL 
(GE-Healthcare). Experiments repeated on at least two 
occasions.
Co-Immunoprecipitation (Co-IP)
HEK293T cells were transfected with plasmids 
encoding GFP-FBXW7-α [28] and FLAG-p53 (WT) 
[64]. 30 hrs after transfection, we used 100 μl of anti-
FLAG-conjugated agarose beads (Sigma-Aldrich) to 
immunoprecipitate p53 or anti-GFP antibody-conjugated 
agarose beads (MBL International) to immunoprecipitate 
FBXW7 from whole cell extracts of the HEK293T 
cells using RIPA buffer (150 mM NaCl) with protease 
inhibitors. After IP, the beads were washed thoroughly 
with RIPA buffer. Immunoprecipitated proteins were 
eluted using 2× SDS loading buffer and then boiled at 
95°C for 4 mins. Denatured proteins were subsequently 
separated on 10% SDS PAGE and immunoblotted against 
anti-GFP and anti-FLAG antibodies as required after 
transferring to polyvinylidene fluoride membranes as 
previously described [65]. The experiments were repeated 
on at least three separate occasions.
Cytotoxicity/viability and colony forming 
efficiency assays
Induction of cellular-proliferation through 
FBXW7-depletion may provide drug-treated cells with 
survival advantages; therefore prior to treatments, 
CRC-cells synchronized in G0-phase by serum-free 
starvation for 18 hrs, and then followed 72 hrs with 
oxaliplatin treatment (Tocris). To determine the cell-
density Sulforhodamine-B (SRB) (Sigma) colorimetric 
assay was performed. In order to fix the cells, 50 μl 
of 30%(w/v) cold Trichloroacetic-acid (TCA) added 
per well and incubated with a final concentration of 
10%-TCA for 60 mins at 4°C. After discarding the 
solution, the plate washed with distilled water and air 
dried. Then, the fixed cells dyed with 0.4%(w/v) SRB, 
in 1%-acetic-acid for 20 mins at RT. Following five-
washings with 1%-acetic-acid and air-drying, the SRB 
was dissolved by adding 200 μl of 10 mM-Trizma-
base. Lastly, a microplate-reader (Bio-Rad) measured 
the absorbance at 540 nm-wavelength [66]. Data were 
elaborated using Microsoft-Office Excel and GraphPad-
Prism softwares (http://www.graphpad.com/scientific-
software/prism/). Colony forming efficiency assay of 
HCT116(FBXW7+/+), HCT116(FBXW7−/−) cells 
treated with 2 different concentrations of oxaliplatin 
for 72 hours for 200 of seeded cells. Images were taken 
following colonies fixation and crystal violet staining on 
day 14 of growth and colonies were counted.
qRT-PCR analysis
For qRT-PCR analysis [28], total RNA was 
isolated from CRC cells using TRIZOL reagent (Sigma-
Aldrich) and purified using the RNeasy mini kit including 
DNase (QIAGEN) according to the manufacturer’s 
instructions (Figure S1). cDNA synthesis was performed 
using Superscript reagents (Invitrogen) according to 
the manufacturer’s instructions. Quantitative real-time 
PCR was accomplished with SYBR green incorporation 
(Platinum Quantitative PCR SuperMix-UDG w/ROX; 
Invitrogen) using an ABI7900HT (Applied Biosystems), 
and the data were analyzed using SDS 2.3 software 
(Applied Biosystems). Results were normalized to those 
obtained with GAPDH, and data are presented as fold 
induction/repression over parental cells. Details of primers 
used are shown in Table S1. All assays were performed in 
triplicate at least three times.
Measuring the level of fluorescence using ImageJ
For quantification of fluorescence intensity, images 
of IFs were converted into binary images using the ImageJ 
program (http://rsbweb.nih.gov/ij/download.html) for 
determining/measuring the level of fluorescence in a 
selected area. We selected the area of the image with Red-
fluorescent (stained with phospho-p53 antibody) first while 
set measurements for area, integrated density and mean. 
Basically with selecting “measure” it provide values. Once 
measurement for red-fluorescent finished, DAPI (blue-
fluorescent) were selected. We have also selected area 
with no fluorescent as background. We have selected 5 
areas per slide. We used the following formula to calculate 
the corrected total cell fluorescence (CTCF). CTCF = 
Integrated Density – (Area of selected fluorescent × 
Mean fluorescence of background readings). Then, we 
have calculated the ratio of average values obtained 
between p53(Ser15)/DAPI (red/blue) for each condition. 
We made a graph and showed % of their relative of 
fluorescence.
Statistical analysis
Statistical analysis was undertaken using SPSS 15.0 
software. All evaluations were done using the unpaired 
two-tailed Student’s t-test. For IHC analysis, the chi-
square test was used and p < 0.05 was considered to 
indicate a significant difference.
Supporting information
Supplemental Information contains Supplementary 
Figure 1, Legend and Supplementary Tables 1, can be 
found with this article online at Oncotarget website.
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